Background: Anlotinib has demonstrated durable clinical benefits in patients with unresectable or metastatic bone and soft-tissue sarcomas.
Methods: 92 patients treated with chemotherapy combined with or without anlotinib were collected and analyzed. The objective response rate (ORR) and disease control rate (DCR) were analyzed. Long-term survival was assessed using the Kaplan-Meier method, including median progression-free survival (mPFS) and overall survival (mOS).
Results: Liposarcoma, synovial sarcoma, and rhabdomyosarcoma were the primary pathological subtypes of the 92 patients. The median age was 46 (range, 11-75) years. The ORR and DCR of the anlotinib-chemotherapy combination used as first-line therapy were 31.9% and 85.1%, respectively. However, the ORR and DCR were only 6.7% and 57.8% in the chemotherapy alone, respectively. Compared with the chemotherapy group, improvements were observed in the mPFS and mOS with anlotinib-based regimen (mPFS, 8.3 vs. 3.0 months; mOS, 59.0 vs. 22.0 months). Anlotinib-associated adverse events were well tolerated and mainly occurred in grades I and II. New anlotinib-related adverse reactions were not noted.
Conclusion: Anlotinib-based regimen as a first-line therapy showed a positive effect on the treatment of unresectable or metastatic BSTSs. The anlotinib-associated adverse events were minor and well tolerated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/0118715206336884241216070930 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and Efficacy of Anlotinib-based Regimen in Patients with Unresectable or Metastatic Bone and Soft-tissue Sarcomas: A Retrospective Institutional Study.
Anticancer Agents Med Chem
January 2025
Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Henan Zhengzhou, 450052, China.
Background: Anlotinib has demonstrated durable clinical benefits in patients with unresectable or metastatic bone and soft-tissue sarcomas.
Methods: 92 patients treated with chemotherapy combined with or without anlotinib were collected and analyzed. The objective response rate (ORR) and disease control rate (DCR) were analyzed.
Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial.
Signal Transduct Target Ther
December 2024
Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Article Synopsis
- * In Cohort A (colorectal cancer), the objective response rate (ORR) was 40.4% with a median progression-free survival (PFS) of 8.7 months, while in Cohort C (non-colorectal/non-esophageal GI cancer), the ORR was 31.8% with a PFS of 5.8 months.
- * The study indicated promising antitumor activity, enabling liver metastasectomy in some patients, without introducing new safety issues.
Efficacy and safety of Anlotinib based neoadjuvant chemotherapy for locally advanced triple negative breast cancer (TNBC).
BMC Cancer
October 2024
Breast Cancer Center, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Article Synopsis
- Anlotinib, a tyrosine kinase inhibitor, was studied for its effectiveness and safety when combined with a chemotherapy regimen (docetaxel, epirubicin, and cyclophosphamide) as neoadjuvant treatment for locally advanced triple-negative breast cancer (TNBC).
- The study involved 18 patients who received an average of nearly six treatment cycles; results showed a high overall response rate of 83.33% and a complete pathological response of 55.6%, indicating significant tumor reduction.
- The treatment had manageable side effects, with 27.8% of patients experiencing severe adverse events, but no participants had to stop treatment due to these effects, suggesting the combined regimen is worth further investigation
CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib.
Mol Cancer
March 2024
Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: Tyrosine kinase inhibitors (TKIs) are crucial in the targeted treatment of advanced colorectal cancer (CRC). Anlotinib, a multi-target TKI, has previously been demonstrated to offer therapeutic benefits in previous studies. Circular RNAs (circRNAs) have been implicated in CRC progression and their unique structural stability serves as promising biomarkers.
View Article and Find Full Text PDFEfficacy and safety of anlotinib-based chemotherapy for locally advanced or metastatic anaplastic thyroid carcinoma.
Endocrine
September 2023
Department of Head and Neck Surgery, West District of The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Purpose: Anaplastic thyroid carcinoma (ATC) is one of the most lethal malignancies with no effective treatment. In this study, we investigated the efficacy and safety of anlotinib-based chemotherapy as first-line therapy for ATC.
Methods: Locally advanced or metastatic (LA/M) ATC patients who never received antitumor treatment of any sort were eligible for this study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!